Efficacy and safety of mirikizumab (LY3074828) in chronic plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials.

ABSTRACT:

Background

Chronic plaque psoriasis is a persistent inflammatory skin condition characterized by erythematous, scaly plaques, significantly impairing the quality of life of affected individuals. Mirikizumab, a humanized monoclonal antibody targeting interleukin-23 (IL-23) p19 subunit, has shown promising efficacy in managing moderate-to-severe cases of this disease. This meta-analysis aims to evaluate the efficacy and safety of mirikizumab in comparison to placebo or other active treatments in this patient population.

Methods

A systematic review of randomized controlled trials (RCTs) was conducted. Eligible studies were identified through searches of major databases. The primary endpoint was clinical response measured by Psoriasis Area and Severity Index (PASI) improvement.

SUBMITTER: Ashraf T 

PROVIDER: S-EPMC12321557 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature